# Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

> **NCT05381038** · PHASE1,PHASE2 · RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 10 (estimated)

## Conditions studied

- Solid Tumor
- Gastrointestinal Cancer
- Breast Cancer

## Interventions

- **DEVICE:** QPOP
- **DEVICE:** CURATE.AI
- **DRUG:** Azacitidine + docetaxel
- **DRUG:** Azacitidine + paclitaxel
- **DRUG:** Azacitidine + irinotecan

## Key facts

- **NCT ID:** NCT05381038
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-13
- **Primary completion:** 2026-10-04
- **Final completion:** 2027-04-04
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05381038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05381038, "Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT05381038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*